乳腺癌中的表皮生长因子受体突变:治疗挑战和前进的道路
Swathi R Shetty1, Trisha Kar1, Amitava Das1
1Department of Applied Biology, Council of Scientific & Industrial Research-Indian Institute of Chemical Technology (CSIR-IICT), Uppal Road, Tarnaka, Hyderabad 500 007, TS, India; Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, UP 201 002, India.
向表皮生长因子受体 (EGFR) 显示出对三阴性乳腺癌 (TNBC) 的承诺. 开发先进的抑制剂对于克服耐药性和改善治疗结果至关重要.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症治疗方法 癌症治疗方法
背景情况:
- 皮表皮生长因子受体 (EGFR) 是一种受体氨酸激酶 (RTK),在侵袭性三阴性乳腺癌 (TNBC) 中经常被上调.
- 结合体的EGFR激活调节了癌细胞的关键过程,包括生长,增殖,迁移和生存.
- 抑制EGFR已经显示出调节乳腺癌干细胞中化学敏感性的潜力.
研究的目的:
- 审查针对乳腺癌EGFR的治疗策略.
- 讨论与EGFR突变和对当前疗法的耐药性相关的挑战.
- 为组合方法提出开发下一代抑制剂的建议.
主要方法:
- 对针对EGFR的治疗方法的文献综述.
- 对抗性机制的分析,包括EGFR突变.
- 探索涉及EGFR抑制剂的组合疗法.
主要成果:
- 已获得临床批准的EGFR抑制剂 (TKI和mAbs) 已用于乳腺癌治疗.
- 由于EGFR突变引起的内在和获得的耐药性限制了当前EGFR-TKI的有效性.
- 建议使用化疗或免疫疗法的组合疗法来克服耐药性.
结论:
- 向EGFR是乳腺癌,特别是TNBC的验证策略.
- EGFR突变是一个重大挑战,需要新的治疗方法.
- 开发用于组合治疗的先进EGFR抑制剂对于改善治疗结果和预防复发至关重要.
更多相关视频
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
08:29Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells
Published on: May 9, 2025
相关概念视频
Mitogens and the Cell Cycle
Targeted Cancer Therapies
There are several types of targeted therapies against...
Clinical Applications of Epidermal Stem Cells
Treatment Resistant Cancers
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Renewal of Skin Epidermal Stem Cells
